Short Interest in Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Increases By 11.2%

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) saw a large growth in short interest in the month of November. As of November 15th, there was short interest totalling 144,000 shares, a growth of 11.2% from the October 31st total of 129,500 shares. Based on an average trading volume of 15,000 shares, the days-to-cover ratio is presently 9.6 days. Currently, 0.5% of the shares of the company are sold short.

Institutional Investors Weigh In On Eupraxia Pharmaceuticals

An institutional investor recently bought a new position in Eupraxia Pharmaceuticals stock. 180 Wealth Advisors LLC acquired a new stake in Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 13,000 shares of the company’s stock, valued at approximately $34,000.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the company. RODMAN&RENSHAW raised Eupraxia Pharmaceuticals to a “strong-buy” rating in a report on Thursday, November 14th. Rodman & Renshaw started coverage on Eupraxia Pharmaceuticals in a research report on Thursday, November 14th. They set a “buy” rating and a $9.00 price objective on the stock.

Eupraxia Pharmaceuticals Stock Up 1.5 %

NASDAQ EPRX traded up $0.05 during trading on Monday, hitting $3.40. 20,552 shares of the stock traded hands, compared to its average volume of 16,617. The company has a market capitalization of $92.76 million and a P/E ratio of -4.65. The firm has a 50-day simple moving average of $2.81 and a 200-day simple moving average of $2.72. Eupraxia Pharmaceuticals has a 12-month low of $2.20 and a 12-month high of $5.58.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company’s lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.